Literature DB >> 25665552

Altered microRNA Expression in Peripheral Blood Mononuclear Cells from Young Patients with Schizophrenia.

Hui-Min Fan1, Xin-Yang Sun, Wei Niu, Lin Zhao, Qiao-Li Zhang, Wan-Shuai Li, Ai-Fang Zhong, Li-Yi Zhang, Jim Lu.   

Abstract

Schizophrenia (SZ) is a debilitating psychotic disorder of unknown etiology, and the diagnosis is essentially based on clinical symptoms. So it is urgent to find an objective and feasible clinical diagnostic index for SZ. MicroRNA array was performed in peripheral blood mononuclear cells (PBMCs) obtained from young SZ patients and gender-, age-, and ethnicity-matched healthy controls. Then, real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to verify the top 10 microRNAs (miRNAs) with the highest fold change values in 55 SZ patients and 28 healthy controls, and 9 miRNAs demonstrate significant differences in expression levels (P < 0.01). Receiver operating characteristic (ROC) curve analysis showed that the combining area under the ROC curve (AUC) of the nine miRNAs was 0.973 (95 % confidence interval (CI): 0.945-1.000). miRNA target gene prediction and functional annotation analysis showed that there were significant enrichments in several gene ontology (GO) biological process and Kyoto encyclopedia of genes and genomes (KEGG) pathways associated with nervous system and brain functions, suggesting that the differentially expressed miRNAs may be involved in mechanism of SZ. We conclude that altered expression of miRNAs in PMBCs might be involved in young SZ pathogenesis and may serve as noninvasive biomarker for SZ diagnosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25665552     DOI: 10.1007/s12031-015-0503-z

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  57 in total

1.  Genetic evidence for association between NOTCH4 and schizophrenia supported by a GWAS follow-up study in a Japanese population.

Authors:  M Ikeda; B Aleksic; K Yamada; Y Iwayama-Shigeno; K Matsuo; S Numata; Y Watanabe; T Ohnuma; T Kaneko; Y Fukuo; T Okochi; T Toyota; E Hattori; S Shimodera; M Itakura; A Nunokawa; N Shibata; H Tanaka; H Yoneda; H Arai; T Someya; T Ohmori; T Yoshikawa; N Ozaki; N Iwata
Journal:  Mol Psychiatry       Date:  2012-05-29       Impact factor: 15.992

2.  Aberrant microRNA expression in peripheral plasma and mononuclear cells as specific blood-based biomarkers in schizophrenia patients.

Authors:  Xin-yang Sun; Jim Lu; Liang Zhang; Hong-tao Song; Lin Zhao; Hui-min Fan; Ai-fang Zhong; Wei Niu; Zhong-min Guo; Yun-hua Dai; Chao Chen; Yan-fen Ding; Li-yi Zhang
Journal:  J Clin Neurosci       Date:  2014-12-06       Impact factor: 1.961

3.  Gene expression abnormalities and oligodendrocyte deficits in the internal capsule in schizophrenia.

Authors:  David Kerns; Ghe S Vong; Kevin Barley; Stella Dracheva; Pavel Katsel; Patrizia Casaccia; Vahram Haroutunian; William Byne
Journal:  Schizophr Res       Date:  2010-05-23       Impact factor: 4.939

4.  The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment.

Authors:  Annamaria Cattaneo; Antonella Sesta; Francesca Calabrese; Gabriela Nielsen; Marco Andrea Riva; Massimo Gennarelli
Journal:  Neuropsychopharmacology       Date:  2010-03-17       Impact factor: 7.853

5.  Association of polymorphisms in the haplotype block spanning the alternatively spliced exons of the NTNG1 gene at 1p13.3 with schizophrenia in Japanese populations.

Authors:  T Ohtsuki; Y Horiuchi; M Koga; H Ishiguro; T Inada; N Iwata; N Ozaki; H Ujike; Y Watanabe; T Someya; T Arinami
Journal:  Neurosci Lett       Date:  2008-02-29       Impact factor: 3.046

6.  The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development.

Authors:  Zhengping Zhang; Yinhe Zha; Wei Hu; Zhen Huang; Zhongfei Gao; Yuhui Zang; Jiangning Chen; Lei Dong; Junfeng Zhang
Journal:  J Biol Chem       Date:  2013-11-06       Impact factor: 5.157

7.  MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia.

Authors:  Chi-Yu Lai; Sung-Liang Yu; Ming H Hsieh; Chun-Houh Chen; Hsuan-Yu Chen; Chun-Chiang Wen; Yung-Hsiang Huang; Po-Chang Hsiao; Chuhsing Kate Hsiao; Chih-Min Liu; Pan-Chyr Yang; Hai-Gwo Hwu; Wei J Chen
Journal:  PLoS One       Date:  2011-06-29       Impact factor: 3.240

Review 8.  The RNA-centred view of the synapse: non-coding RNAs and synaptic plasticity.

Authors:  Neil R Smalheiser
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-09-26       Impact factor: 6.237

9.  MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.

Authors:  Saif Ullah Munshi; Harekrushna Panda; Prasida Holla; Bharat Bhushan Rewari; Shahid Jameel
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

Review 10.  Expression, regulation and function of microRNAs in multiple sclerosis.

Authors:  Xinting Ma; Juhua Zhou; Yin Zhong; Linlin Jiang; Ping Mu; Yanmin Li; Narendra Singh; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Int J Med Sci       Date:  2014-06-02       Impact factor: 3.738

View more
  16 in total

Review 1.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors:  Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal:  World J Psychiatry       Date:  2016-03-22

2.  The schizophrenia risk gene MIR137 acts as a hippocampal gene network node orchestrating the expression of genes relevant to nervous system development and function.

Authors:  Nikkie F M Olde Loohuis; Nael Nadif Kasri; Jeffrey C Glennon; Hans van Bokhoven; Sébastien S Hébert; Barry B Kaplan; Gerard J M Martens; Armaz Aschrafi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-02-27       Impact factor: 5.067

Review 3.  Diagnostic and therapeutic potential of microRNAs in neuropsychiatric disorders: Past, present, and future.

Authors:  Begum Alural; Sermin Genc; Stephen J Haggarty
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-04-09       Impact factor: 5.067

4.  Diagnostic value of blood-derived microRNAs for schizophrenia: results of a meta-analysis and validation.

Authors:  Sha Liu; Fuquan Zhang; Xijin Wang; Yin Yao Shugart; Yingying Zhao; Xinrong Li; Zhifen Liu; Ning Sun; Chunxia Yang; Kerang Zhang; Weihua Yue; Xin Yu; Yong Xu
Journal:  Sci Rep       Date:  2017-11-10       Impact factor: 4.379

Review 5.  Circulating miRNAs as Diagnostic Biomarkers for Parkinson's Disease.

Authors:  Anna Elisa Roser; Lucas Caldi Gomes; Jonas Schünemann; Fabian Maass; Paul Lingor
Journal:  Front Neurosci       Date:  2018-09-05       Impact factor: 4.677

Review 6.  Non-Coding RNA as Novel Players in the Pathophysiology of Schizophrenia.

Authors:  Andrew Gibbons; Madhara Udawela; Brian Dean
Journal:  Noncoding RNA       Date:  2018-04-12

7.  Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings.

Authors:  Lukasz Smigielski; Vinita Jagannath; Wulf Rössler; Susanne Walitza; Edna Grünblatt
Journal:  Mol Psychiatry       Date:  2020-01-06       Impact factor: 15.992

8.  Insights into psychosis risk from leukocyte microRNA expression.

Authors:  C D Jeffries; D O Perkins; S D Chandler; T Stark; E Yeo; J Addington; C E Bearden; K S Cadenhead; T D Cannon; B A Cornblatt; D H Mathalon; T H McGlashan; L J Seidman; E F Walker; S W Woods; S J Glatt; M Tsuang
Journal:  Transl Psychiatry       Date:  2016-12-13       Impact factor: 6.222

9.  Chaihu-Shugan-San exerts an antidepressive effect by downregulating miR-124 and releasing inhibition of the MAPK14 and Gria3 signaling pathways.

Authors:  Qiong Liu; Ning-Ning Sun; Zheng-Zhi Wu; Da-Hua Fan; Mei-Qun Cao
Journal:  Neural Regen Res       Date:  2018-05       Impact factor: 5.135

10.  Review and Meta-Analyses of TAAR1 Expression in the Immune System and Cancers.

Authors:  Lisa M Fleischer; Rachana D Somaiya; Gregory M Miller
Journal:  Front Pharmacol       Date:  2018-06-26       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.